Houston's spike in VC deals, accelerator acquired, new coworking, and more innovation news

Short stories

Looking into venture capital deal growth, new coworking coming to town, and more Houston innovation news. Getty Images

Houston has seen some big headlines this month when it comes to innovation news — and you could have missed something.

From a report on venture capital funding last year and new coworking coming to town to a Houston investor selling her accelerator company, here's the latest batch of short stories in Houston innovation.

Houston sees spike in venture capital deals in 2019

Houston saw more venture capital funding in 2019 compared to 2018. Chart via crunchbase.com

Overall, 2019 was a good one for Texas venture capital deals. Austin had a record turnout of money invested in startups. Austin companies raised over $1.8 billion, which put the state capitol in the top 10 cities based on money raised, according to a report by Crunchbase.

And this Texas VC roundup on Crunchbase focused a lot of the Austin funding and didn't harp too much on the other Texas cities. But Houston's numbers are also record breaking. The Bayou City raised nearly $400 million last year — with the bulk of that being recorded in Q2 of 2019.

Houston's recorded $399.6 million in VC deals surpasses 2018's recorded funding by almost $20 million, but if you look at PitchBook and the National Venture Capital Association's data, the amount is higher. According to Pitchbook, the total funding raised in 2019 in Houston deals surprasses $600 million across 98 deals.

Houston investor-founded accelerator acquired

Houston investor ​Diana Murakhovskaya has sold her New York-based accelerator program. ​Photo courtesy of The Artemis Fund

New York-based Monarq Incubator, a venture capital-focused accelerator program for women, has been acquired by Female Founders Alliance. Monarq was co-founded by Diana Murakhovskaya, one of the three co-founders of Houston-based, female-focused The Artemis Fund.

Since its founding in 2017, Monarq accelerated 32 companies that have then gone on to raise more than $10 million in venture capital. The combined company, according to a news release, now represents the largest network of women and non-binary venture-scalable founders.

"FFA and Monarq share more than just a mission – we share founder DNA," says Leslie Feinzaig, CEO of Female Founders Alliance, in the release. "Our two communities and accelerator programs were built by women founders, for women founders. We are uniquely able to build programming that accelerates the success of women in our space, and now along with founder cred, we have scale and a national footprint. I am so excited for what we can achieve in this next stage of FFA."

The acquisition means a heightened focus on The Artemis Fund for Murakhovskaya.

"Now that I am full time focused on raising and investing with Artemis, it's great to know that our community and founders will have a home and provide us with a great source of deal flow," she says in an email to InnovationMap.

A new coworking company to enter Houston with Galleria-area office

New Galleria-area coworking is coming later this year. Photo via serendipitylabs.com

Serendipity Labs Coworking, which has over 100 coworking spaces across the United States and United Kingdom, announced its plans to enter six new markets this year. Houston is among the new locations for the coworking company.

Expected top open in the fall, the Houston coworking space will be a 28,331-square-foot space on the 20th floor of the Marathon Oil Tower at 5555 San Felipe St. in the Galleria area. According to the release, Cameron Coworking, a division of Cameron Management, will be the development partner for the Houston market.

"By partnering with asset owners of office, retail and residential buildings and then managing the Labs, we bring our operational expertise and marketing power, and we assure the upscale service standards of one of the top national flexible workplace networks will be met at every location," says John Arenas, chairman and CEO of Serendipity Labs, in a news release.

MassChallenge Texas opens applications for second cohort

Applications are open for MassChallenge Texas' second Houston cohort. Courtesy of MassChallenge

At an event on January 29 in both Houston and Austin, MassChallenge Texas opened applications for its 2020 cohorts

The 4-month accelerator program is set to begin in June and online applications close March 9. Prizes include six months of free office space and up to $250,000 in equity free investment. Click here for more information.

Houston entrepreneur named to 2020 class of Presidential Leadership Scholars

Houston startup founder, Reda Hicks, has been named a Presidential Leadership Scholar. Photo via presidentialleadershipscholars.org

For this sixth year, the Presidential Leadership Scholars announced its class of veterans, educators, physicians, public servants, and corporate professionals to participate in the program. Reda Hicks, founder of GotSpot was named as one of the 60 scholars. The program began this week in Washington D.C..

"I cannot wait to work with, and learn from, these exceptional leaders," Hicks shares on LinkedIn. "And through the program, I will be working on RescueSpot, a community resiliency application of GotSpot Inc."

Another Houstonian was selected too — Ganesh Betanabhatla, who is the managing partner and chief investment officer at Ramas Capital Management.

Ion Smart Cities Accelerator opens applications for second cohort

Aatonomy, a member of the first cohort, walked away with a cash prize at Demo Day. F. Carter Smith/Station Houston

The second cohort for the Ion Smart Cities Accelerator Program has opened applications online. The first cohort, focused on resilience and mobility, is currently in pilot mode. Cohort II will be focused on water purification/quality, air quality, and clean technology.

The applications will close on Monday, February 17, and startups that are selected will be notified the week of March 2.

The program, which was announced in June, is backed by Microsoft and Intel and named its first cohort last fall. The demo day for the first cohort took place last month. The accelerator has its own space and prototyping lab in downtown Houston, which opened in September.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings